Elevar Therapeutics: FDA regulations evolve as science changes: Elevar Therapeutics COO

Elevar Therapeutics, developing the rivoceranib and camrelizumab combination therapy as a first-line treatment for liver cancer, has shared the latest regulatory trends, emphasizing that U.S. FDA regulations are changing as science evolves.Seong H. Jang, chief operating officer of Elevar Therapeutic